Helix Pharmaceuticals

Helix BioPharma is a clinical-stage biopharmaceutical company headquartered in Richmond Hill, Ontario, specializing in the development of next-generation oncology therapies. The company's core technology, the DOS47 platform, utilizes a proprietary urease-based approach to neutralize the acidic microenvironment of solid tumors, thereby enhancing the effectiveness of concurrent treatments. Its lead product candidate, L-DOS47, is a recombinant fusion protein targeting CEACAM5-expressing tumors, currently undergoing clinical evaluation for non-small cell lung cancer. Beyond its flagship program, Helix is expanding its portfolio to include treatments for pancreatic cancer and exploring the potential of its platform in combination with chimeric antigen receptor T-cell (CAR-T) therapies. The company is publicly traded on the Toronto Stock Exchange and maintains strategic collaborations with leading cancer research institutions.